
News
3 days ago•3 min read
The Hidden Cost of Diabetes Tech: Why 'Affordable Access' Is a Trojan Horse for Pharma Profit
The unified call for affordable diabetes technology masks a deeper regulatory battle. Who truly benefits from this 'access' push?
D
DailyWorld Editorial
